NDRA ENDRA Life Sciences (NDRA) Insider Trading, Ownership & Congress Trades
Medical Devices · Electromedical & electrotherapeutic apparatus · CIK 0001681682
Activist 13D
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
5
13F, latest reported quarter
What the filings say about NDRA
Activist stakes (13D), 180 days
1 filing
Largest: 15.1% of the class
ENDRA Life Sciences insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for ENDRA Life Sciences Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 2.5% of the 146,012 shares held after it.
- No other insider bought within 30 days.
- 5 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider UBS Group AG bought about $2.0K of NDRA on Aug 27, 2024, the largest insider purchase at the company since 2023; 5 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 buys), the last on Dec 9, 2022.
- +20.3% median (+12.7% mean) 90-day return after 4 previous buys.
- The trade is 43.9% of the 34,139 shares held after it.
- 1 other insider bought within 30 days.
- 5 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Technology Officer Thornton Michael Milos bought about $24.8K of NDRA on May 18, 2023; 1 other insider bought within 30 days and 5 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 81.4% of the 102,434 shares held after it.
- 1 other insider bought within 30 days.
- 5 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director DIGIANDOMENICO ANTHONY bought about $100.0K of NDRA on May 2, 2023, the largest insider purchase at the company on our record; 1 other insider bought within 30 days and 5 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Aug 22, 2022.
- +22.7% median (+10.9% mean) 90-day return after 3 previous buys.
- The trade is 7.8% of the 19,139 shares held after it.
- 1 other insider bought within 30 days.
- 5 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Technology Officer Thornton Michael Milos bought about $5.1K of NDRA on Dec 9, 2022; 1 other insider bought within 30 days and 5 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Aug 22, 2022.
- +24.3% median (+24.3% mean) 90-day return after 2 previous buys.
- The trade is 6.1% of the 162,857 shares held after it.
- 1 other insider bought within 30 days.
- 5 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Tokman Alexander Y bought about $1.7K of NDRA on Nov 23, 2022; 1 other insider bought within 30 days and 5 funds added in the latest 13F quarter.13 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
5 funds bought in last quarter
below 97% of Medical Devices
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
1.8% of the float short (float per yahoo 2026-10-27) · 1.4 days to cover · settled 2026-10-15
below 66% of Medical Devices
The situation: each line is one rule over one dataset
ASP Isotopes Inc. disclosed a 5%+ stake (15.1%) in the last six months.
What changed in the last 30 days
Oct 8ASP Isotopes Inc. filed a 13D for 15.1%
Oct 8LHE LNG Holdings LLC filed a 13D for 15.1%
Watch NDRA
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-2.8%12M
13D/G stakeForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns NDRA: institutional holders (13F)
13F holdings, latest reported quarter
59,272 sh
$315.9K
29,924 sh
$159.5K
28,400 sh
$151.4K
14,910 sh
$79.5K
10,121 sh
$53.9K
Congress trades in NDRA
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
13D: intends to influence · 13G: passive
ASP Isotopes Inc.
Activist 13D · 2026-10-08
15.1%
LHE LNG Holdings LLC
Activist 13D · 2026-10-08
15.1%
NDRA planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Anthony DiGiandomenico
Filed 2026-06-25
$425.0K
NDRA mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$80.2K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$39.1K position · as of 2026-06-30
0.0%
Fidelity Series Total Market Index Fund
$8.8K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Mr. Michelon
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$215.2K
$194.8K
$148.1K
-70%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
An activist crossed the 5% line with declared intent.
The record shows 5 funds added last quarter. Each figure is a federal filing, dated the day it went public.
NDRA financials
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$0
four quarters, 2019-01-01 to 2019-12-31
Revenue, TTM NDRA
| FY Dec 2025 | $0 |
| FY Dec 2024 | $0 |
| FY Dec 2023 | $0 |
| FY Dec 2022 | $0 |
| FY Dec 2021 | $0 |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Net margin, TTM NDRA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$4.8M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM NDRA
| FY Dec 2025 | -$5.2M |
| FY Dec 2024 | -$7.4M |
| FY Dec 2023 | -$9.6M |
| FY Dec 2022 | -$13.0M |
| FY Dec 2021 | -$11.2M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | -$1.6M |
| Sep 2025 | -$1.2M |
| Jun 2025 | -$1.1M |
| Mar 2025 | -$1.3M |
| Dec 2024 | -$1.5M |
| Sep 2024 | -$1.7M |
At each fiscal year end
Single quarter
Debt to equity
0.00x
long-term 2024-12-31 (18 months older than the period end) plus current 2024-12-31 (18 months older than the period end); equity 2026-06-30
Debt to equity NDRA
| FY Dec 2025 | 0.00x |
| FY Dec 2024 | 0.00x |
| FY Dec 2023 | 0.01x |
| FY Dec 2022 | 0.00x |
| FY Dec 2021 | 0.05x |
| Jun 2026 | 0.00x |
| Mar 2026 | 0.00x |
| Dec 2025 | 0.00x |
| Sep 2025 | 0.00x |
| Jun 2025 | 0.00x |
| Mar 2025 | 0.00x |
| Dec 2024 | 0.00x |
| Sep 2024 | 0.00x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt to cover
Cash flow to debt NDRA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -335.23x |
| FY Dec 2022 | -448.30x |
| FY Dec 2021 | -20.35x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-152.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity NDRA
| FY Dec 2025 | -291.6% |
| FY Dec 2024 | -280.0% |
| FY Dec 2023 | -156.4% |
| FY Dec 2022 | -146.5% |
| FY Dec 2021 | -125.1% |
| Jun 2026 | -152.0% |
| Mar 2026 | -412.6% |
| Dec 2025 | -291.6% |
| Sep 2025 | -236.3% |
| Jun 2025 | -167.5% |
| Mar 2025 | -358.4% |
| Dec 2024 | -280.0% |
| Sep 2024 | -149.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-110.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets NDRA
| FY Dec 2025 | -169.2% |
| FY Dec 2024 | -205.4% |
| FY Dec 2023 | -125.5% |
| FY Dec 2022 | -119.0% |
| FY Dec 2021 | -103.8% |
| Jun 2026 | -110.1% |
| Mar 2026 | -221.0% |
| Dec 2025 | -169.2% |
| Sep 2025 | -154.8% |
| Jun 2025 | -132.3% |
| Mar 2025 | -237.4% |
| Dec 2024 | -205.4% |
| Sep 2024 | -110.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital NDRA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-141.7%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed NDRA
| FY Dec 2025 | -165.8% |
| FY Dec 2024 | -223.1% |
| FY Dec 2023 | -156.8% |
| FY Dec 2022 | -139.2% |
| FY Dec 2021 | -120.3% |
| Jun 2026 | -141.7% |
| Mar 2026 | -248.4% |
| Dec 2025 | -165.8% |
| Sep 2025 | -193.3% |
| Jun 2025 | -151.5% |
| Mar 2025 | -294.8% |
| Dec 2024 | -223.1% |
| Sep 2024 | -122.8% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing NDRA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | 0.28x |
| Jun 2025 | 0.29x |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$5.5M
market value at close 2026-10-26 on 2026-08-14 shares, plus long-term 2024-12-31 (18 months older than the period end) plus current 2024-12-31 (18 months older than the period end), minus cash 2026-06-30
Enterprise value NDRA
| FY Dec 2025 | $4.5M |
| FY Dec 2024 | $131.6K |
| FY Dec 2023 | $31.4B |
| FY Dec 2022 | $450.0B |
| FY Dec 2021 | $1.0T |
| Jun 2026 | $5.0M |
| Mar 2026 | $5.0M |
| Dec 2025 | $4.5M |
| Sep 2025 | $2.2M |
| Jun 2025 | $783.1K |
| Mar 2025 | -$924.4K |
| Dec 2024 | $131.6K |
| Sep 2024 | $504.8M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-67.0%
TTM free cash flow over market value at close 2026-10-26
FCF yield NDRA
| FY Dec 2025 | -98.4% |
| FY Dec 2024 | -220.7% |
| FY Dec 2023 | -0.0% |
| FY Dec 2022 | -0.0% |
| FY Dec 2021 | -0.0% |
| Jun 2026 | -71.5% |
| Mar 2026 | -87.1% |
| Dec 2025 | -98.4% |
| Sep 2025 | -126.0% |
| Jun 2025 | -216.0% |
| Mar 2025 | -284.4% |
| Dec 2024 | -220.7% |
| Sep 2024 | -1.6% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing NDRA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Operating income | -$5.8M | -$10.8M | -$10.5M | -$13.2M |
| Net income | -$7.0M | -$11.5M | -$10.1M | -$13.2M |
| EPS (diluted) | -8.93 | -56.94 | -2,766.85 | n/a |
| Operating cash flow | -$5.2M | -$7.4M | -$9.5M | -$12.8M |
| Cash | $762.4K | $3.2M | n/a | $4.9M |
| Long-term debt | n/a | $0 | $0 | $0 |
SEC XBRL, fiscal years, as known on 2026-10-28
NDRA Stock Sonar score 4/7 axes
Find similar shapesCompareNDRA ranks highest on financial health (99th percentile) and risk and compliance (40th), and lowest on institutional and government (3rd), among Medical Devices peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
NDRA filings, in plain words
Read the full summary
1 activist Schedule 13D filing in the last 180 days declared an intent to influence the company, the largest for 15.1% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
